Host-Based Diagnostics & Prognostics

ACESO currently uses a combination of unbiased and targeted laboratory testing ‘multi-omic’ platforms (transcriptomic, proteomic, metabolomic etc.) to perform a comprehensive characterization of the temporal dynamics of the host response to infection. Our vision is to translate this systems biology approach to develop and deploy rapid point-of-care diagnostics/prognostics in resource-limited settings across the globe. We envision a time where host-immune biomarker-driven sepsis endotypes leading to evidence-based clinical management will become standard of care in sepsis/severe infections.

To that end, ACESO is engaged in observational studies of sepsis in Cambodia, Ghana, Liberia, Uganda, Madagascar, Peru and the United States. Patients presenting to participating hospitals with severe illness and a suspected infection are enrolled in an observational study of sepsis. A variety of biological samples are collected to examine the molecular characteristics of each patient’s host response to infection.

Capturing large amounts of data to characterize the state of the biological system as a whole and then using advanced mathematical analysis to identify networks and associations of factors appears to be a powerful tool in understanding pathogenesis, diagnosis/prognosis and targets for intervention. These approaches are critical in discovering novel pathways; dissecting pathogen- or pathogen-class specific host responses; diagnostics based on biomarkers for pathogen-class, risk and severity assessment; biomarker-based patient stratification creating target patient profiles for therapeutic classes of drugs and biologics; validating therapeutic targets; clinical management strategies; and pharmacodynamic or (therapeutic) response biomarkers for prognostics.